These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32734665)

  • 1. Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study.
    Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
    Dermatol Ther; 2020 Nov; 33(6):e14110. PubMed ID: 32734665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.
    Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
    J Dermatol; 2017 Apr; 44(4):363-369. PubMed ID: 27774694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis.
    Genre F; Armesto S; Corrales A; López-Mejías R; Remuzgo-Martínez S; Pina T; Ubilla B; Mijares V; Martín-Varillas JL; Rueda-Gotor J; Portilla V; Dierssen-Sotos T; González-López MA; González-Vela MDC; Blanco R; Llorca J; Hernández JL; González-Gay MÁ
    J Dermatolog Treat; 2017 Dec; 28(8):726-730. PubMed ID: 28489469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis.
    Zdanowska N; Owczarczyk-Saczonek A; Czerwińska J; Nowakowski JJ; Kozera-Żywczyk A; Owczarek W; Zdanowski W; Placek W
    Medicina (Kaunas); 2020 Sep; 56(9):. PubMed ID: 32942670
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
    Bissonnette R; Tardif JC; Harel F; Pressacco J; Bolduc C; Guertin MC
    Circ Cardiovasc Imaging; 2013 Jan; 6(1):83-90. PubMed ID: 23204039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.
    Andersen CSB; Kvist-Hansen A; Siewertsen M; Enevold C; Hansen PR; Kaur-Knudsen D; Zachariae C; Nielsen CH; Loft N; Skov L
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha inhibition could reduce biomarkers of endothelial dysfunction in patients with moderate to severe psoriasis: A 52-week echo-Doppler based quasi-experimental study.
    Molina-Leyva A; Garrido-Pareja F; Ruiz-Carrascosa JC; Ruiz-Villaverde R
    Med Clin (Barc); 2018 Jun; 150(12):465-468. PubMed ID: 29089115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study.
    Pina T; Corrales A; Lopez-Mejias R; Armesto S; Gonzalez-Lopez MA; Gómez-Acebo I; Ubilla B; Remuzgo-Martínez S; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Dermatol; 2016 Nov; 43(11):1267-1272. PubMed ID: 27062420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Dermatol; 2016 Apr; 43(4):389-94. PubMed ID: 26364678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
    Mehta NN; Shin DB; Joshi AA; Dey AK; Armstrong AW; Duffin KC; Fuxench ZC; Harrington CL; Hubbard RA; Kalb RE; Menter A; Rader DJ; Reilly MP; Simpson EL; Takeshita J; Torigian DA; Werner TJ; Troxel AB; Tyring SK; Vanderbeek SB; Van Voorhees AS; Playford MP; Ahlman MA; Alavi A; Gelfand JM
    Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007394. PubMed ID: 29776990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis.
    Dowlatshahi EA; van der Voort EA; Arends LR; Nijsten T
    Br J Dermatol; 2013 Aug; 169(2):266-82. PubMed ID: 23550658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
    Luan L; Han S; Wang H; Liu X
    Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab and methotrexate affect the concentrations of regulatory cytokines (interleukin-10, transforming growth factor-β1, and interleukin-35) in patients with plaque psoriasis.
    Zdanowska N; Owczarczyk-Saczonek A; Czerwińska J; Nowakowski JJ; Kozera-Żywczyk A; Owczarek W; Zdanowski W; Placek W
    Dermatol Ther; 2020 Nov; 33(6):e14153. PubMed ID: 32770629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
    Manriquez J; Alsina-Gibert M
    Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
    Piaserico S; Osto E; Famoso G; Zanetti I; Gregori D; Poretto A; Iliceto S; Peserico A; Tona F
    Atherosclerosis; 2016 Aug; 251():25-30. PubMed ID: 27236353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
    Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis.
    Pirro M; Stingeni L; Vaudo G; Mannarino MR; Ministrini S; Vonella M; Hansel K; Bagaglia F; Alaeddin A; Lisi P; Mannarino E
    Eur J Prev Cardiol; 2015 Aug; 22(8):1027-35. PubMed ID: 24906366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY; Chu TW; Cheng YP; Tsai TF
    PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis.
    Kaur S; Zilmer K; Leping V; Zilmer M
    J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1328-33. PubMed ID: 21349112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.